Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

NCT03107962 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

DRUG: Pembrolizumab (PD-1 Blocking Antibody)

Sponsor

Mingzhi Zhang